ClinicalTrials.gg
Active, not recruitingNCT02790853Updated Oct 15, 2026

Multimodal Imaging for Surveillance in Patients With Oral Potentially Malignant Disorders

An Early Phase 1 interventional study of Biopsy and Fluorescence Imaging in Dysplasia, Lip and Oral Cavity Carcinoma and Oral Disorder, sponsored by M.D. Anderson Cancer Center. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by M.D. Anderson Cancer Center · Early Phase 1, Interventional, and Diagnostic

How we know

Updated Oct 15, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
63
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies in Mouth Neoplasms by M.D. Anderson Cancer Center — 4 open to participants now, 8 under way, none of them phase 3. Mouth Neoplasms · M.D. Anderson Cancer Center.

Enrollment
10th of 18
63 · median 76
Started
2016
with 1 other
Phase 1
6 of 25
none open now
Registered
19th of 25
by date

Among the 25 studies in Mouth Neoplasms by M.D. Anderson Cancer Center, this one is the 10th largest by enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2016, is one of 6 in phase 1, and was the 19th registered.

Mouth Neoplasms

447 studies on the registry are indexed under Mouth Neoplasms; 131 are open to participants now.

Browse Mouth Neoplasms studies →

Open to participants now

4 of the 25 studies in Mouth Neoplasms by M.D. Anderson Cancer Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 97 Mouth Neoplasms studies recruiting now, 58 (60%) set no upper age limit and 23 (24%) stop at 75 or younger; 5 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Mouth Neoplasms by M.D. Anderson Cancer Center, or all of them as a file.
02

Study summary

This early phase I trial studies how well multimodal imaging works for surveillance in patients with oral potentially malignant disorders. New types of imaging devices may help doctors decide if a lesion in the mouth is pre-cancerous or cancerous.

Read the detailed description

PRIMARY OBJECTIVES:

I. To compare standard white light examination to multimodal imaging for detection of high grade dysplasia and carcinoma during follow-up examinations of patients with oral potentially malignant disorders (OPMD).

SECONDARY OBJECTIVES:

I. To determine qualitative and quantitative diagnostic assessment of patients who agree to undergo imaging and have images of sufficient quality.

II. To compare expression of molecular biomarkers to results from white light examination, multimodal imaging and pathologic assessment in a subset of patients who have invasive biopsies or resection.

III. To compare cytologic results from brush biopsy specimens to white light examination and multimodal imaging results.

OUTLINE:

Participants undergo PS2.1/PS3 imaging and high-resolution microendoscope imaging with proflavine hemisulfate applied to the mucosa. Patients also undergo brush biopsy and incisional biopsy. Procedures are repeated every 3-4 months for 2 years.

After completion of study treatment, patients are followed up at 30 days.

03

Conditions studied

  • Dysplasia
  • Lip and Oral Cavity Carcinoma
  • Oral Disorder
  • Premalignant Lesion
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who are willing to participate.
  • Adult subjects with: a. clinically evident oral premalignant lesion (OPL) or suspicious oral mucosal lesion. or b. pathologic diagnosis of dysplasia or c. history of resected oral cancer or d. oral potentially malignant disorder (OPMD) or e. history of tobacco and/or alcohol exposure.
  • Ability to understand and willingness to sign a written document (ICD).

Exclusion criteria

Exclusion Criteria:

  • Known allergy to proflavine or acriflavine.
  • Pregnant females.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Early Phase 1
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
63 participants (actual)

Study arms

  • Experimental
    Diagnostic (multimodal imaging, biopsy)

    Participants undergo PS2.1/PS3 imaging and high-resolution microendoscope imaging with proflavine hemisulfate applied to the mucosa. Patients also undergo brush biopsy and incisional biopsy. Procedures are repeated every 3-4 months for 2 years.

    Procedure: Biopsy · Procedure: Fluorescence Imaging · Procedure: High-Resolution Microendoscopy · Drug: Proflavine Hemisulfate

Interventions

  • ProcedureBiopsy

    Undergo brush biopsy and incisional biopsy

    Also known as: Bx

  • ProcedureFluorescence Imaging

    Undergo PS2.1/PS3 imaging

  • ProcedureHigh-Resolution Microendoscopy

    Undergo HRME imaging

    Also known as: HRME

  • DrugProflavineStudies of ProflavineProflavine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Applied on mucosa

06

What researchers measure

Primary outcomes

  1. Detection of high grade dysplasia and carcinoma

    Will compare standard white light examination to multimodal imaging for detection of high grade dysplasia and carcinoma during follow-up examinations of patients with oral potentially malignant disorders (OPMD).

    Time frame: Up to 2 years

Secondary outcomes

  1. Diagnostic assessment

    Will determine qualitative and quantitative diagnostic assessment of patients who agree to undergo imaging and have images of sufficient quality.

    Time frame: Up to 2 years

  2. Biomarker analysis

    Will compare expression of molecular biomarkers to results from white light examination, multimodal imaging and pathologic assessment in a subset of patients who have invasive biopsies or resection.

    Time frame: Up to 2 years

  3. Cytologic results

    Will compare cytologic results from brush biopsy specimens to white light examination and multimodal imaging results.

    Time frame: Up to 2 years

07

Study locations

1 site
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started May 2016 (actual). Primary completion is estimated for May 2028, 144 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: primary completion May 2026 → May 2028 and completion May 2026 → May 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2016
First posted
Jun 6, 2016
StartActual
May 25, 2016
Primary completionEst.
May 31, 2028was May 2026
CompletionEst.
May 31, 2028was May 2026
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
May 31, 2026→May 31, 2028
Oct 15, 2026
Study completion
May 31, 2026→May 31, 2028
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Primary completion May 31, 2026→May 31, 2028
    Study completion May 31, 2026→May 31, 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT02790853
Responsible party
Sponsor
First posted
Jun 6, 2016
Start date
May 25, 2016
Primary completion
May 31, 2028 (estimated)
Completion
May 31, 2028 (estimated)
Last update
Oct 15, 2026

Study contacts

Ann Gillenwater
principal investigator · M.D. Anderson Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Proflavine

Start the discussion